Drs. Binder and Puchner contributed equally to this work.
Tumor necrosis factor–inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor–driven model of rheumatoid arthritis†
Article first published online: 25 FEB 2013
Copyright © 2013 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 65, Issue 3, pages 608–617, March 2013
How to Cite
Binder, N. B., Puchner, A., Niederreiter, B., Hayer, S., Leiss, H., Blüml, S., Kreindl, R., Smolen, J. S. and Redlich, K. (2013), Tumor necrosis factor–inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor–driven model of rheumatoid arthritis. Arthritis & Rheumatism, 65: 608–617. doi: 10.1002/art.37797
This is a publication of the Joint and Bone Center for Diagnosis, Research and Therapy of Musculoskeletal Disorders, Medical University of Vienna.
- Issue published online: 25 FEB 2013
- Article first published online: 25 FEB 2013
- Accepted manuscript online: 28 DEC 2012 11:29AM EST
- Manuscript Accepted: 8 NOV 2012
- Manuscript Received: 15 JAN 2012
- European Community Seventh Framework Programme. Grant Number: project Masterswitch: HEALTH-F2-2008-223404
- Abbott Immunology
- 15Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the Anti–Tumor Necrosis Factor Trial in Rheumatoid Arthritis With Concomitant Therapy study. Arthritis Rheum 2005; 52: 1020–30., , , , , , et al.
- 16Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the Trial of Etanercept and Methotrexate with Radiographic and Patient Outcomes. Arthritis Rheum 2006; 54: 3119–25., , , , .
- 23RANK signaling is not required for TNFα-mediated increase in CD11hi osteoclast precursors but is essential for mature osteoclast formation in TNFα-mediated inflammatory arthritis. J Bone Miner Res 2004; 19: 207–13., , , , , .
- 25Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35–45., , , , , , et al.
- 28Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis 2002; 61: 1047–54., , , , , , et al.
- 29High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after anti–tumor necrosis factor α treatment. Arthritis Rheum 2002; 46: 1744–53., , , , , , et al.
- 31CD16 (FcRγIII) as a potential marker of osteoclast precursors in psoriatic arthritis. Arthritis Res Ther; 12: R14., , , , , , et al.
- 37Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor–induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 2004; 50: 277–90., , , , , , et al.